Common Antibiotic Doxycycline Linked to Rare Clotting Abnormality in a Child, Case Report Warns

Doxycycline is one of the most widely used antibiotics in modern medicine, a tetracycline-class drug that physicians reach for everything from acne to tick-borne infections. In pediatric wards across Asia, its star has risen even further in recent years, because it has become a first-line treatment for macrolide-resistant Mycoplasma pneumoniae, a stubborn respiratory bacterium that no longer responds to the azithromycin that once handled it easily. But a new case report from clinicians in Guangzhou, China, published in BMC Pediatrics, suggests that even this workhorse drug may carry a risk that has flown almost entirely under the radar: a serious disturbance of blood clotting. The researchers describe what they believe is the first documented case of doxycycline-induced coagulation dysfunction associated with macrolide-resistant Mycoplasma pneumoniae infection, a finding they hope will prompt clinicians to watch more closely for an adverse reaction that is likely rarer than it is recognized.

The case centered on a pediatric patient with confirmed macrolide-resistant Mycoplasma pneumoniae infection who had been placed on oral doxycycline, a standard and generally well-tolerated choice for this pathogen. After five days of treatment, laboratory testing revealed something alarming: the child’s activated partial thromboplastin time, or APTT, had climbed to more than twice the normal value. The APTT is one of the two central screening tests of the coagulation system, measuring how long it takes blood to clot through the intrinsic pathway, the cascade of proteins that acts when blood encounters damaged vessel walls. A doubling of that time is not a subtle laboratory blip; it signals a substantial slowing of the clotting machinery and, in some patients, a genuine risk of abnormal bleeding.

What made the finding particularly puzzling, and clinically important, was its isolation. In many coagulation disorders, both major screening tests go awry together: the prothrombin time, or PT, which measures the extrinsic pathway, and the APTT, which measures the intrinsic pathway, rise in tandem. Isolated APTT prolongation, with a normal PT, points the diagnostic finger in a narrower set of directions, toward problems with specific factors such as factor VIII, IX, XI or XII, toward the presence of certain inhibitors, or, as the authors of this report explore at length, toward disruptions in the vitamin K–dependent clotting system. The rarity of isolated APTT prolongation as a drug reaction is precisely why this case caught the attention of the clinical team.

To establish whether doxycycline was genuinely responsible, the researchers turned to the World Health Organization’s standardized causality assessment framework for adverse drug reactions, a structured method that weighs timing, alternative explanations, prior reports, and the response to drug withdrawal. Their conclusion: doxycycline was a likely cause of the child’s coagulation dysfunction. That formal designation matters, because distinguishing a drug reaction from the many other things that can disturb clotting in a sick child, including the infection itself, requires disciplined causal reasoning rather than suspicion alone. The consequences were tangible, too. The coagulation abnormality extended the patient’s hospital stay, which under standard pharmacovigilance definitions classifies the event as a serious adverse drug reaction, not merely an incidental laboratory curiosity.

The heart of the paper, and its most thought-provoking section, is the authors’ exploration of how a tetracycline antibiotic might interfere with blood clotting in the first place. Their analysis focuses on the vitamin K cycle, the biochemical loop that keeps the clotting system supplied with functional proteins. In that cycle, vitamin K must be converted to its active reduced form, vitamin K hydroquinone, by the enzyme vitamin K epoxide reductase, known as VKOR. Vitamin K hydroquinone then serves as the essential cofactor for gamma-glutamyl carboxylase, or GGCX, the enzyme that chemically modifies the vitamin K–dependent clotting factors so they can bind calcium and assemble into a working clot. When the cycle runs smoothly, factors II, VII, IX and X are continuously carboxylated and ready; when it falters, non-functional precursors accumulate and clotting slows.

This is, notably, the same pathway targeted by warfarin, the classic anticoagulant, which works by inhibiting VKOR and starving the clotting factors of their vitamin K–dependent activation. The report’s authors use this well-mapped biochemistry as the framework for hypothesizing how doxycycline might produce an isolated APTT prolongation, examining the vitamin K epoxide, the hydroquinone intermediate, and the enzymatic steps that link them. While the exact mechanism remains to be fully established, the discussion represents an unusually detailed mechanistic exploration for a single case report, reflecting the team’s concern that a rare reaction may be hiding in plain sight within one of medicine’s most common prescriptions. Because only some patients exposed to the drug develop the abnormality, any plausible mechanism would need to account for that selectivity, whether through individual differences in vitamin K status, metabolism, or the interplay with concurrent infection.

The clinical team did not work in a vacuum. The paper is anchored by a comprehensive review of the existing literature on doxycycline and coagulation, which confirmed just how rarely such reactions have been reported despite the drug’s enormous global footprint. That scarcity is a double-edged sword for clinicians: it offers reassurance that the reaction is uncommon, but it also means that most practitioners will never have encountered it and may not think to check for it. The authors’ conclusion is measured but pointed. Doxycycline-related coagulation abnormalities may be rare in the literature, they write, but the potential risk should not be overlooked, and vigilance is warranted, particularly in patients who already have underlying coagulation disorders or who are receiving anticoagulant medications at the same time.

That vigilance, in practical terms, translates into a specific and inexpensive recommendation: monitoring the APTT for early detection of the abnormality. The activated partial thromboplastin time is a routine, rapidly performed laboratory test available in virtually every hospital, which makes surveillance for this particular reaction far more feasible than surveillance for many other rare drug toxicities. For a child on doxycycline for resistant Mycoplasma pneumoniae, a periodic APTT could catch a developing coagulation dysfunction before it produces symptoms, allowing the drug to be stopped or the patient observed before bleeding complications arise. The authors’ suggestion is especially relevant in regions where macrolide resistance has made doxycycline a frontline therapy for large numbers of children, multiplying the number of exposures and, statistically, the opportunities for rare reactions to surface.

The broader significance of the report lies in the tension it highlights between a drug’s reputation and its pharmacology. Doxycycline earned its reputation for safety through decades of use, and nothing in this single case overturns that standing. But rare adverse reactions are, by their nature, invisible to ordinary clinical experience and emerge only through careful documentation of individual cases, the kind of pharmacovigilance that this report exemplifies. The event occurred in a patient treated at institutions in Guangzhou, with the study approved by the ethics committee of The Third Affiliated Hospital of Guangzhou Medical University under approval number LW-2025-141, and with written informed consent for publication provided by the patient’s mother. The research team included Yiyang Li, Si Huang, Liman Li, Weihua Li, Jian Gu and Lichun Xie, with contributions spanning the Third Affiliated Hospital of Sun Yat-sen University, the Third Affiliated Hospital of Guangzhou Medical University, and Foshan Fosun Chancheng Hospital.

Published online on 24 September 2026 as an open-access article in BMC Pediatrics, the paper arrives at a moment when macrolide-resistant Mycoplasma pneumoniae is increasingly prevalent and doxycycline prescriptions are climbing in step. For the clinicians prescribing it, the message is not to abandon the drug, which remains a first-line and generally safe treatment, but to recognize that even familiar medications can surprise us. A prolonged APTT in a child on doxycycline, particularly when the prothrombin time remains normal, should now join the differential diagnosis as a possible drug reaction rather than being dismissed as a laboratory oddity. For researchers, the case opens a mechanistic question, the precise interaction between tetracyclines and the vitamin K–dependent carboxylation pathway, that a single report cannot fully answer. And for the pharmacovigilance community, it is a reminder that the safety profile of any drug is never finished being written, and that attentive clinicians documenting unusual cases remain one of the most important early-warning systems in medicine.

Subject of Research: Doxycycline-associated isolated APTT prolongation and the vitamin K mechanism in a pediatric patient

Article Title: Pediatric doxycycline-induced isolated APTT prolongation: a rare case with exploration of the vitamin K mechanism

Article References: Li, Y., Huang, S., Li, L., Li, W., Gu, J., & Xie, L. (2026). Pediatric doxycycline-induced isolated APTT prolongation: a rare case with exploration of the vitamin K mechanism. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07536-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07536-5

Keywords: doxycycline, coagulation dysfunction, APTT, vitamin K, macrolide-resistant Mycoplasma pneumoniae, adverse drug reaction, pediatrics, antibiotics, VKOR, gamma-glutamyl carboxylase, pharmacovigilance, case report